Efficacy and Safety of Secukinumab 150  mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study

ConclusionsSecukinumab 150  mg, with or without loading regimen, provided rapid and sustained decreases in the signs and symptoms of patients with AS, but the differences were not statistically significant at week 16 due to higher than expected placebo responses. The responses and safety profile were consistent with previous phase 3 studies and sustained through 2 years.Trial registrationClinicalTrials.gov identifier, NCT02159053.FundingNovartis Pharma AG, Basel, Switzerland.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research